NASDAQ : BNTC
Benitec Biopharma Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 8.74 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 304.88M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 293.71M |
| Enterprise Value | 114.50M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 34.88M |
| Shares Outstanding | 34.88M |
| Shares Change (YoY) | +28.58% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 0.24% |
| Owned by Institutions (%) | 51.25% |
| Float | 19.28M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.70 |
| P/TBV Ratio | 1.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 34.00 |
| Quick Ratio | 33.68 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -33.21% |
| Return on Assets (ROA) | -22.67% |
| Return on Invested Capital (ROIC) | -23.19% |
| Return on Capital Employed (ROCE) | -28.88% |
| Weighted Average Cost of Capital (WACC) | 5.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.90M |
| Employee Count | 24 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.25 |
| 52-Week Price Change | -48.04% |
| 50-Day Moving Average | 10.29 |
| 200-Day Moving Average | 11.52 |
| Relative Strength Index (RSI) | 39.57 |
| Average Volume (20 Days) | 169,771 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.99M |
| Short Previous Month | 2.04M |
| Short % of Shares Out | 5.71% |
| Short % of Float | 10.33% |
| Short Ratio (days to cover) | 9.77 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -51.19M |
| Pretax Income | -45.55M |
| Net Income | -45.55M |
| EBITDA | -51.13M |
| EBIT | -51.19M |
| Earnings Per Share (EPS) | -$0.98 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 179.97M |
| Total Debt | 762,000 |
| Net Cash | 179.21M |
| Net Cash Per Share | $5.14 |
| Equity (Book Value) | 177.01M |
| Book Value Per Share | 5.14 |
| Working Capital | 176.34M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -16.52M |
| Capital Expenditures | -105,000 |
| Depreciation & Amortization | 58,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -16.62M |
| FCF Per Share | -$0.48 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -28.58% |
| Shareholder Yield | -28.58% |
| Earnings Yield | -11.62% |
| FCF Yield | -5.45% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $23.29 |
| Price Target Difference | 176.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 26, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |